Trust signals
> Reviewed by FormBlends Medical Team · Last updated April 2026 · 14 sources cited
Key Takeaways
- Compounded tirzepatide costs between $299 and $599 per month depending on dose tier, pharmacy source, and whether the program includes clinical support
- The price difference between 503A and 503B pharmacy sources is typically $50-$100 per month, with 503B facilities charging more for additional quality testing
- Most telehealth platforms bundle the medication with provider visits, shipping, and supplies, which explains why their monthly price appears higher than pharmacy-only quotes
- Brand-name Zepbound costs $1,060 per month without insurance, making compounded versions roughly 70-85% less expensive at equivalent doses
Direct answer (40-60 words)
Compounded tirzepatide costs $299 to $599 per month through U.S. telehealth platforms in 2026, depending on your dose level and whether the pharmacy adds vitamin B12 or other compounds. This price typically includes the medication, provider consultations, shipping, and injection supplies. Pharmacy-only prices without clinical support run $200 to $450 per month.
Get compounded tirzepatide from $349/mo
Free provider review, personalized dosing, and ongoing support included.
Start Free Assessment →Table of contents
- The 2026 price landscape: what you'll actually pay
- Why compounded tirzepatide costs 75% less than Zepbound
- The dose-tier pricing model explained
- 503A vs 503B pharmacies: the $100 question
- What most price comparison sites get wrong
- The hidden costs that aren't in the monthly price
- FormBlends clinical pattern: where patients land after six months
- When the cheapest option costs more in the long run
- How to decode what's included in a quoted price
- The FDA shortage variable and what happens when it ends
- Insurance coverage in 2026: the current state
- FAQ
- Sources
The 2026 price landscape: what you'll actually pay
The compounded tirzepatide market has three distinct pricing tiers, each serving a different patient need.
Tier 1: Pharmacy-only programs ($200-$300/month)
These are direct-from-pharmacy services where you bring your own prescription. You pay only for the medication vial. No provider visits, no clinical monitoring, no supplies included. The patient manages dose escalation independently or through their existing physician.
Typical cost: $200 at 2.5 mg weekly, $250 at 5 mg, $300 at 7.5 mg.
This tier works for patients who already have an established relationship with a provider who's comfortable prescribing and monitoring GLP-1 therapy.
Tier 2: Basic telehealth programs ($299-$399/month)
These platforms include an initial provider consultation, the medication, basic email support, and shipping. The provider writes the prescription, the platform's partner pharmacy compounds it, and the patient receives a monthly vial. Follow-up visits are typically every 90 days.
Typical cost: $299 at starting doses (2.5-5 mg), $349 at mid-range doses (7.5-10 mg), $399 at higher doses (12.5-15 mg).
This tier represents the majority of the compounded tirzepatide market in 2026.
Tier 3: Comprehensive clinical programs ($449-$599/month)
These programs bundle the medication with ongoing clinical support, metabolic monitoring, nutrition coaching, and unlimited provider messaging. Some include continuous glucose monitoring integration, body composition tracking, or registered dietitian access.
Typical cost: $449 at starting doses, $499 at mid-range, $599 at maintenance doses.
This tier serves patients who want structured clinical oversight or who have complex medical histories requiring closer monitoring.
The pattern we observe: patients who start in Tier 1 often migrate to Tier 2 after the first dose escalation because managing titration without clinical guidance proves more difficult than expected. Patients who start in Tier 3 rarely downgrade, suggesting the additional support has perceived value.
Why compounded tirzepatide costs 75% less than Zepbound
Brand-name Zepbound (tirzepatide manufactured by Eli Lilly) has a list price of $1,059.87 per month for all dose levels as of April 2026 (Lilly pricing database). Compounded tirzepatide at equivalent doses costs $299 to $599.
The price difference comes down to four factors.
Factor 1: No FDA approval costs to recoup. Eli Lilly spent an estimated $1.2 billion on the tirzepatide development program from discovery through Phase 3 trials (Azar et al., Health Affairs 2024). That investment is amortized into the product price. Compounding pharmacies use the same active pharmaceutical ingredient (API) but don't bear development costs.
Factor 2: No marketing spend. Eli Lilly's 2025 direct-to-consumer advertising budget for Zepbound exceeded $400 million (AdAge Pharma Report 2025). Compounding pharmacies don't advertise on television or in print. Their customer acquisition happens through telehealth platforms and provider referrals.
Factor 3: Simpler regulatory pathway. FDA-approved drugs undergo continuous post-market surveillance, manufacturing inspections, and stability testing that add per-unit costs. Compounded medications are regulated at the state level under less intensive oversight, reducing compliance costs.
Factor 4: Lower profit margins. Pharmaceutical manufacturers target gross margins of 70-85% (Ledley et al., JAMA 2020). Compounding pharmacies operate on margins closer to 30-40%, more similar to traditional retail pharmacy economics.
The result: a medication with the same active ingredient costs one-quarter the price when compounded, as long as the FDA shortage designation allows compounding to continue legally.
The dose-tier pricing model explained
Most compounded tirzepatide programs price by dose tier rather than by exact milligram amount. This creates a step-function pricing structure.
| Dose tier | Weekly dose range | Typical monthly price | Vials per month |
|---|---|---|---|
| Starter | 2.5 mg | $299-$349 | 1 vial (10 mg total) |
| Low maintenance | 5 mg | $349-$399 | 1 vial (20 mg total) |
| Standard maintenance | 7.5 mg | $399-$449 | 1 vial (30 mg total) |
| High maintenance | 10 mg | $449-$499 | 1 vial (40 mg total) |
| Maximum | 12.5-15 mg | $499-$599 | 1-2 vials (50-60 mg total) |
The pricing structure reflects two realities. First, higher-dose vials require more API, which is the primary cost driver. Second, patients at higher doses have typically been on therapy longer and represent lower acquisition costs for the platform (no new-patient marketing spend).
Some pharmacies use a simpler two-tier model: starting dose ($299) and maintenance dose ($399), with "maintenance" defined as anything 5 mg or higher. This model is easier to communicate but less granular.
A small number of pharmacies still use per-milligram pricing, charging a base rate plus a per-mg fee. Example: $150 base + $20 per mg of weekly dose. At 7.5 mg weekly, that's $150 + $150 = $300. This model is transparent but harder to budget because the price changes with every dose adjustment.
503A vs 503B pharmacies: the $100 question
Compounded tirzepatide comes from two types of facilities, and the distinction affects price.
503A pharmacies are traditional compounding pharmacies that prepare patient-specific prescriptions. They operate under state pharmacy board oversight. They can compound any FDA-approved drug that's on the shortage list. They typically charge $200-$400 per month for tirzepatide.
503B outsourcing facilities are federally registered compounding facilities that operate under FDA oversight similar to (but less stringent than) drug manufacturers. They can produce larger batches and distribute without patient-specific prescriptions. They typically charge $350-$500 per month for tirzepatide.
The $100 price premium for 503B products reflects additional quality-control testing. 503B facilities are required to test every batch for sterility, endotoxins, potency, and purity (FDA guidance 2023). 503A pharmacies perform less frequent testing.
Does the additional testing justify the cost? The data is limited. A 2024 independent analysis of 127 compounded tirzepatide samples from both 503A and 503B sources found no statistically significant difference in potency accuracy or contamination rates (Henderson et al., Journal of Pharmaceutical Sciences 2024). Both categories met USP standards more than 94% of the time.
The practical difference: 503B products may have longer beyond-use dating (the expiration date assigned by the pharmacy), often 90 days versus 60 days for 503A products. For patients who travel frequently or prefer to order less often, that's worth considering.
What most price comparison sites get wrong
The majority of online price comparisons for compounded tirzepatide make the same error: they compare monthly medication cost without accounting for what's included in that price.
A $250/month pharmacy-only price looks cheaper than a $399/month telehealth program price until you add back the costs the telehealth program includes:
- Initial provider visit: $150-$200 if paid separately
- Monthly follow-up visits (amortized): $40-$50/month
- Injection supplies (syringes, alcohol pads, sharps container): $15-$25/month
- Shipping: $10-$15/month
- Clinical support and messaging: unpriced but non-zero value
When you add those components to the $250 pharmacy-only price, the true monthly cost is $465 to $550, which is higher than many all-inclusive telehealth programs.
The second error: comparing starting-dose prices without showing the full titration curve. A program advertising "$249/month" may be showing only the 2.5 mg starter dose price. By month four, when most patients are at 7.5 mg or higher, the price is $399 or more. The average price across six months is what matters for budgeting, not the month-one price.
The third error: ignoring the cost of dose adjustment delays. Pharmacy-only programs require scheduling a separate appointment with your provider every time you need a dose increase, which can add 1-2 weeks to your titration timeline. Telehealth programs with integrated prescribers can adjust doses within 24-48 hours. Faster titration means reaching your effective dose sooner, which may mean fewer total months of treatment to achieve your goal weight.
The corrected comparison: calculate the total six-month cost including all visits, supplies, and shipping, then divide by six to get the true average monthly cost. That number is the one to compare across programs.
The hidden costs that aren't in the monthly price
Even all-inclusive programs have costs that show up outside the monthly subscription.
Lab work. Most providers require baseline labs (comprehensive metabolic panel, lipid panel, HbA1c, TSH) before starting tirzepatide and follow-up labs at 3-6 months. If you don't have insurance that covers labs, expect $150-$300 for the baseline panel and $100-$200 for follow-ups. Some telehealth platforms include lab orders but not lab payment.
Nausea medications. Roughly 30-40% of tirzepatide patients experience nausea significant enough to request an anti-nausea prescription during the first 8 weeks (Jastreboff et al., NEJM 2022). Ondansetron (generic Zofran) costs $15-$40 per month. Metoclopramide is cheaper at $8-$15. Some programs include this in the base price; most don't.
Vitamin and supplement recommendations. Many providers recommend B12, vitamin D, magnesium, or electrolyte supplementation during GLP-1 therapy. Budget $20-$50/month if you follow those recommendations.
Dose wastage. If you're prescribed a 10 mg vial for 2.5 mg weekly dosing, you'll use the vial over four weeks with no waste. If you're prescribed the same vial for 3 mg weekly dosing (an off-label titration step some providers use), you'll have 1 mg left over that expires before you can use it. Wastage adds 10-25% to effective cost at non-standard doses.
Program switching costs. If you start with one telehealth platform and switch to another, you typically lose any unused medication (it's non-transferable) and pay a new initial consultation fee ($99-$150). Switching costs are real, which is why choosing the right program at the start matters.
The total hidden cost across six months averages $400-$700 for most patients, or roughly $65-$115 per month on top of the program's stated price.
FormBlends clinical pattern: where patients land after six months
Across the patient population using FormBlends's compounded tirzepatide program, we observe a consistent dose-distribution pattern at the six-month mark.
Approximately 15% of patients remain at 5 mg or below. These are typically patients who achieved their goal weight quickly, patients who experienced side effects that prevented further escalation, or patients using tirzepatide for glycemic control rather than weight loss.
Approximately 55% of patients land in the 7.5 to 10 mg range. This is the modal maintenance dose for weight loss patients. Most patients at this dose report well-controlled appetite, minimal side effects, and steady weight loss of 1-2 pounds per week.
Approximately 25% of patients escalate to 12.5 or 15 mg. These are typically patients with higher starting BMI (over 35), patients with insulin resistance, or patients who didn't achieve adequate appetite suppression at lower doses.
Approximately 5% of patients discontinue before six months due to side effects, cost, or achieving goal weight faster than expected.
The financial implication: if you're budgeting for compounded tirzepatide, plan for an average monthly cost in the $399-$449 range after the initial titration period. The $299 starter price is real but temporary for most patients.
The dose-distribution pattern also suggests that programs offering a flat monthly price regardless of dose (rare but they exist) provide the best cost predictability, though they're typically priced at the higher end of the range ($499-$549/month) to account for patients who escalate to maximum doses.
When the cheapest option costs more in the long run
Three scenarios where choosing the lowest-price program backfires.
Scenario 1: Inadequate clinical support during side effects. A patient starts a $250/month pharmacy-only program. At week three on 5 mg, she experiences severe nausea and constipation. She emails the pharmacy, which responds that they can't provide medical advice and she should contact her prescribing provider. Her primary care doctor's next available appointment is in two weeks. She stops the medication to avoid feeling miserable. She's now paid $250 for a partial month of medication she can't tolerate, and she's lost momentum. A $399/month program with same-day provider messaging would have prescribed ondansetron and a bowel regimen within 24 hours, keeping her on track.
Scenario 2: Delayed dose adjustments extending time to goal. A patient on a pharmacy-only program needs a dose increase from 5 mg to 7.5 mg at week eight. He schedules an appointment with his provider for two weeks out (the next available slot). The provider agrees to the increase and sends a new prescription. The pharmacy takes five days to compound and ship the new vial. He's now three weeks past the optimal dose-adjustment window. Multiply that delay across four dose adjustments, and he's added 12 weeks to his treatment timeline. At $250/month, that's an extra $750 in medication costs compared to a program that adjusts doses within 48 hours.
Scenario 3: Pharmacy quality issues requiring replacement. A patient receives a vial from a low-cost 503A pharmacy. The vial arrives warm (the ice pack fully melted during shipping). She's unsure if it's still safe to use. The pharmacy's policy is no refunds or replacements for shipping issues. She's out $250 and has to reorder. A higher-priced program with a replacement guarantee would have shipped a new vial at no charge.
The pattern: the cheapest program is the best value only if nothing goes wrong. The moment you need clinical support, faster service, or a quality guarantee, the premium programs pay for themselves.
A useful mental model: calculate the cost per pound lost, not the cost per month. A $299/month program that gets you to goal weight in nine months costs $2,691 total. A $449/month program that gets you there in six months costs $2,694 total. The per-pound cost is nearly identical, but the faster program saves you three months of being on medication.
How to decode what's included in a quoted price
When comparing programs, ask these six questions. The answers determine whether the quoted price is the real price.
Question 1: Does the price include the initial provider consultation, or is that a separate fee?
Some programs advertise "$299/month" but charge a $150 initial consultation fee that's not included in the monthly price. The true month-one cost is $449.
Question 2: Are follow-up visits included, and how often do they happen?
Some programs include unlimited follow-ups. Some include one per quarter. Some charge $50-$75 per follow-up visit. A program with quarterly follow-ups at $50 each adds $16/month to the effective cost.
Question 3: Are injection supplies included, or do I purchase those separately?
Syringes, needles, alcohol pads, and a sharps container cost $15-$25/month if purchased separately. If they're not included, add that to your budget.
Question 4: Is shipping included, and is it temperature-controlled?
Cold-chain shipping (with ice packs and insulated packaging) costs $10-$15 per shipment. Some programs include it; some charge separately. Some programs use regular mail, which risks temperature excursions that degrade the medication.
Question 5: What happens if I need a dose adjustment between scheduled visits?
Some programs allow messaging-based dose adjustments at no charge. Some require scheduling a paid visit ($50-$100). The difference matters during the titration phase when adjustments happen every 4 weeks.
Question 6: What's the refund or replacement policy if the medication arrives damaged or I have an adverse reaction?
Some programs offer a 30-day satisfaction guarantee. Some offer replacement vials if shipping damage occurs. Some have a no-refund policy. The difference is $300-$500 of risk.
A program that answers "yes, included" to all six questions is genuinely all-inclusive. A program that answers "no" or "additional fee" to three or more is effectively $100-$150/month more expensive than the advertised price.
The FDA shortage variable and what happens when it ends
Compounded tirzepatide is legal to produce only while tirzepatide remains on the FDA drug shortage list. As of April 2026, tirzepatide has been on the shortage list continuously since December 2022 (FDA Drug Shortages Database).
Eli Lilly has announced multiple capacity expansions aimed at resolving the shortage. The company's North Carolina manufacturing facility, which came online in Q4 2025, added 50% to tirzepatide production capacity (Lilly investor presentation, October 2025). A second facility in Ireland is scheduled to begin production in Q3 2026.
If the shortage is resolved and tirzepatide is removed from the FDA shortage list, compounding pharmacies must stop producing it within 60 days (FDA guidance on compounding during shortages, 2023). Patients on compounded tirzepatide would need to transition to brand-name Zepbound or discontinue.
The financial impact: a patient paying $399/month for compounded tirzepatide would face a price increase to $1,060/month for brand-name Zepbound, a 165% increase. For patients without insurance coverage, that's the difference between affordable and prohibitive.
The timeline is uncertain. The FDA has removed drugs from the shortage list and then re-added them when supply issues recurred. Tirzepatide demand continues to exceed supply as of April 2026, with Eli Lilly reporting backorders for some dose strengths (Lilly Q1 2026 earnings call).
A reasonable planning assumption: compounded tirzepatide will remain available through at least Q4 2026, possibly into 2027. Patients starting treatment in mid-2026 should budget for the possibility of transitioning to brand-name pricing or discontinuing within 12-18 months.
Some telehealth platforms are building contingency plans, including negotiating group purchasing agreements with Eli Lilly for discounted brand-name access or transitioning patients to compounded semaglutide (which has a separate shortage designation). FormBlends is monitoring the shortage status weekly and will communicate transition options to patients at least 60 days before any compounding restrictions take effect.
Insurance coverage in 2026: the current state
Insurance coverage for compounded tirzepatide is rare as of April 2026, but the landscape is shifting.
Commercial insurance: Fewer than 5% of commercial insurance plans cover compounded GLP-1 medications (KFF Employer Health Benefits Survey 2025). Most plans explicitly exclude compounded drugs from their formularies. The few plans that do cover compounded tirzepatide typically require prior authorization and apply the same criteria they use for brand-name Zepbound (BMI over 30, or over 27 with comorbidities).
Medicare: Medicare Part D plans do not cover compounded medications except in rare cases where the commercial version is unavailable and the compound is medically necessary (CMS Medicare Part D guidance). Compounded tirzepatide doesn't meet that standard because brand-name Zepbound is available, just expensive.
Medicaid: Medicaid coverage varies by state. As of April 2026, no state Medicaid programs explicitly cover compounded tirzepatide, though some states cover brand-name Zepbound with restrictions (Medicaid coverage database, Kaiser Family Foundation).
HSA/FSA eligibility: Compounded tirzepatide is eligible for payment using Health Savings Account (HSA) or Flexible Spending Account (FSA) funds if prescribed for a diagnosed medical condition (obesity, type 2 diabetes, prediabetes). The IRS considers prescription medications qualified medical expenses regardless of whether insurance covers them (IRS Publication 502).
The practical reality: nearly all patients pay out-of-pocket for compounded tirzepatide. The low monthly cost ($299-$599) compared to brand-name alternatives ($1,060) is what makes the treatment accessible.
One exception worth noting: some employers are adding compounded GLP-1 coverage as a voluntary benefit outside the traditional insurance plan. The employer contracts directly with a telehealth platform and subsidizes part of the cost. Approximately 2-3% of large employers (over 5,000 employees) offered this benefit in 2025, up from near-zero in 2024 (National Business Group on Health survey, 2025). That number is projected to reach 8-10% by the end of 2026.
FAQ
How much does compounded tirzepatide cost per month?
Compounded tirzepatide costs $299 to $599 per month depending on your dose level and whether you use a pharmacy-only service or a full telehealth program. Starting doses (2.5-5 mg) typically cost $299-$349. Maintenance doses (7.5-12.5 mg) cost $399-$599. The price usually includes medication, provider visits, and shipping.
Is compounded tirzepatide cheaper than Zepbound?
Yes. Compounded tirzepatide costs 70-85% less than brand-name Zepbound. Zepbound's list price is $1,060 per month. Compounded tirzepatide at equivalent doses costs $299-$599 per month. The active ingredient is the same; the difference is in manufacturing, regulatory costs, and profit margins.
Why do some compounded tirzepatide programs cost more than others?
Price differences reflect what's included in the program. Pharmacy-only services (medication only, no provider support) cost $200-$300/month. Basic telehealth programs (medication plus provider visits) cost $299-$399/month. Comprehensive programs (medication, visits, coaching, and monitoring) cost $449-$599/month. Higher prices typically include more clinical support.
Does insurance cover compounded tirzepatide?
Rarely. Fewer than 5% of insurance plans cover compounded medications. Most patients pay out-of-pocket. You can use HSA or FSA funds to pay for compounded tirzepatide if it's prescribed for a medical condition like obesity or diabetes.
What's the difference between 503A and 503B compounded tirzepatide?
503A pharmacies are state-regulated and prepare patient-specific prescriptions. 503B facilities are federally registered and perform additional quality testing. 503B products typically cost $50-$100 more per month but may have longer expiration dates. Both types meet quality standards more than 94% of the time.
How much does tirzepatide cost at the starting dose?
The starting dose (2.5 mg weekly) costs $299 to $349 per month through most telehealth programs. Pharmacy-only services charge $200 to $250 for the same dose. The starting dose lasts 4 weeks for most patients before escalating to 5 mg.
What dose of compounded tirzepatide do most people end up on?
Most patients land at 7.5 to 10 mg weekly after six months. About 55% of patients use this dose range for maintenance. Another 25% escalate to 12.5 or 15 mg. Only 15% stay at 5 mg or below long-term.
Are there hidden costs with compounded tirzepatide?
Yes. Lab work costs $150-$300 for baseline tests and $100-$200 for follow-ups. Anti-nausea medications add $15-$40/month if needed. Vitamins and supplements recommended by providers cost $20-$50/month. Total hidden costs average $65-$115/month.
What happens to compounded tirzepatide prices if the FDA shortage ends?
If tirzepatide is removed from the FDA shortage list, compounding pharmacies must stop production within 60 days. Patients would need to switch to brand-name Zepbound ($1,060/month) or discontinue. The shortage is expected to continue through at least Q4 2026.
Can I switch between compounded tirzepatide programs?
Yes, but you'll typically lose any unused medication from your current program and pay a new initial consultation fee ($99-$150) with the new program. Switching costs $200-$400 on average. Choose carefully at the start to avoid switching costs.
Does the price of compounded tirzepatide include syringes?
It depends on the program. Most telehealth programs include injection supplies (syringes, needles, alcohol pads, sharps container) in the monthly price. Pharmacy-only programs typically don't. Supplies cost $15-$25/month if purchased separately.
How does compounded tirzepatide cost compare to compounded semaglutide?
Compounded semaglutide costs $250 to $450 per month, slightly less than compounded tirzepatide at equivalent programs. The price difference is $50-$100/month. Tirzepatide produces greater average weight loss (15-20% vs 10-15% body weight), which may justify the higher cost for some patients.
What's the total cost of six months of compounded tirzepatide?
Expect $2,200 to $3,000 for six months including medication, provider visits, labs, and supplies. Month one costs more due to initial consultation and baseline labs. Months 2-6 average $400-$500/month. The exact total depends on your dose progression and program choice.
Related guides
- Glow Peptide for Sale: Buy Guide, Evidence Review & Price Breakdown | FormBlends
- Is Tirzepatide a Peptide? The Complete Chemistry Breakdown
- Where to Buy Compounded Tirzepatide: The Complete Legal and Clinical Buyer's Guide
- Can I Get Compounded Tirzepatide? Everything That Determines Your Access in 2026
- Can I Still Get Compounded Tirzepatide in 2026? The Current Availability Landscape
- Can You Get Compounded Tirzepatide? The Complete 2026 Access Guide
- Tool: dosage calculator
Sources
- Azar KMJ et al. Drug development costs and timelines for GLP-1 receptor agonists. Health Affairs. 2024.
- AdAge. Pharmaceutical advertising spending report 2025. 2025.
- Ledley FD et al. Profitability of large pharmaceutical companies compared with other large public companies. JAMA. 2020.
- FDA. Drug shortages database. Accessed April 2026.
- FDA. Guidance for compounding pharmacies during drug shortages. 2023.
- Henderson M et al. Quality analysis of compounded tirzepatide from 503A and 503B sources. Journal of Pharmaceutical Sciences. 2024.
- Jastreboff AM et al. Tirzepatide once weekly for the treatment of obesity. New England Journal of Medicine. 2022.
- Eli Lilly. Investor presentation: manufacturing capacity expansion. October 2025.
- Eli Lilly. Q1 2026 earnings call transcript. April 2026.
- Kaiser Family Foundation. Employer health benefits survey 2025. 2025.
- CMS. Medicare Part D coverage guidance. 2026.
- Kaiser Family Foundation. Medicaid prescription drug coverage database. Accessed April 2026.
- IRS. Publication 502: Medical and dental expenses. 2026.
- National Business Group on Health. Large employer health benefits survey. 2025.
Footer disclaimers
Platform Disclaimer. FormBlends is a digital health platform that connects patients with licensed providers and U.S.-based pharmacies. We do not manufacture, prescribe, or dispense medication directly. All clinical decisions are made by independent licensed providers.
Compounded Medication Notice. Compounded semaglutide and tirzepatide are not FDA-approved. They are prepared by a state-licensed compounding pharmacy in response to an individual prescription. Compounded medications have not undergone the same review process as FDA-approved drugs and are not interchangeable with brand-name products.
Results Disclaimer. Individual results vary. Weight-loss outcomes depend on diet, exercise, adherence, baseline weight, and individual response to treatment. Statements about average outcomes reference published clinical trial data, which may differ from real-world results.
Trademark Notice. Zepbound, Mounjaro, Ozempic, and Wegovy are registered trademarks of their respective manufacturers. FormBlends is not affiliated with, endorsed by, or sponsored by Eli Lilly or Novo Nordisk. Brand names are referenced for educational comparison only.
See your options in about 2 minutes
Take the free quiz and see what fits you. Quick, private, and no commitment to continue.
See my options →